Offer Request Form

Order list is empty

Shikari® (S-ATC) Anti-Cetuximab ELISA w/confirmation

Enzyme immunoassay for the quantitative determination of antibodies to Cetuximab (Erbitux®) in serum and plasma with confirmation.

This kit has been especially developed for the quantitative antibodies to cetuximab in serum and plasma samples

Cetuximab (Erbitux®)  was associated to the development of anti-Cetuximab antibodies, even some were reported to be neutralizing, in various percentages of patients during therapy with the drug EGFR®. This might lead to severe complications. This kit can be efficiently used for monitoring anti-Cetuximab antibodies during therapy and offers the clinician a tool for decision on possible preventive measures such as possible addition of immunosuppressive drug to reduce anti-Cetuximab antibodies. .

All SHIKARI® ELISA kits are suitable for biosimilar work. 

All SHIKARI® ELISA kits are produced under ISO 13485 quality system and have CE IVD mark.

For technical inquiry, please contact techsupport@matriksbiotek.com

Required Volume (µl) 20
Total Time (min) 140
Sample Serum, plasma
Sample Number 96
Detection Limit (ng/mL) 30
Spike Recovery (%) Between 85-115
Shelf Life (year) 1
Assay type Quantitative
Species Reactivity Human
Storage conditions Store at +4°C. Please refer to protocols.
Shipping conditions At room temperature
# File Action
Instructions For Use Download
Safety Data Sheet (SDS) Download
Validation Report Download

Publications with this drug

# File Action
Peña-Cabia, Silvia, et al. "Assessment of exposure-response relationship for cetuximab in patients with metastatic colorectal cancer and head and neck cancer." Farmacia Hospitalaria 46.1 (2022): 21-26. Visit Link
Zhang, Jinhua, et al. "sRNA-based screening chromosomal gene targets and modular designing Escherichia coli for high-titer production of aglycosylated immunoglobulin G." ACS Synthetic Biology 9.6 (2020): 1385-1394. Visit Link
Zhang, Jinhua, et al. "Synthetic sRNA‐based engineering of Escherichia coli for enhanced production of full‐length immunoglobulin G." Biotechnology Journal 15.5 (2020): 1900363. Visit Link
柴田海斗. "Simple and rapid LC-MS/MS method for the absolute determination of cetuximab in human serum using an immobilized trypsin." (2019). Visit Link
Peña Cabia, Silvia. "Evaluación de la relación exposición-respuesta de bevacizumab y de cetuximab en cáncer colorrectal metastásico y de cetuximab en cáncer de cabeza y cuello." (2022). Visit Link